MedTrace Logo

Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects

NCT04432610 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-12-20

No results posted yet for this study

Summary

This is a randomized, double-blind, crossover study in healthy adult subjects. Each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. All subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.

Conditions

  • Bisoprolol Adverse Reaction
  • Nebivolol Adverse Reaction

Interventions

DRUG

Bisoprolol versus Nebivolol

All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period

Sponsors & Collaborators

  • Clinical Hospital Center Zemun

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2030-01-31
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04432610 on ClinicalTrials.gov